Back to Search
Start Over
Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations.
- Source :
-
Journal of addictive diseases [J Addict Dis] 2023 Jan-Mar; Vol. 41 (1), pp. 53-63. Date of Electronic Publication: 2022 Mar 31. - Publication Year :
- 2023
-
Abstract
- Background: There is limited knowledge on the causes of large variations in serum methadone concentrations and dose requirements.<br />Objectives: We investigated the impact of the degree of liver fibrosis on dose-adjusted steady-state serum methadone concentrations.<br />Methods: We assessed the clinical and laboratory data of 155 Norwegian patients with opioid use disorder undergoing methadone maintenance treatment in outpatient clinics in the period 2016-2020. A possible association between the degree of liver fibrosis and dose-adjusted serum methadone concentration was explored using a linear mixed-model analysis.<br />Results: When adjusted for age, gender, body mass index, and genotypes of CYP2B6 and CYP3A5 , the concentration-to-dose ratio of methadone did not increase among the participants with liver fibrosis (Coefficient: 0.70; 95% CI: -2.16, 3.57; P : 0.631), even among those with advanced cirrhosis (-0.50; -4.59, 3.59; 0.810).<br />Conclusions: Although no correlation was found between the degree of liver stiffness and dose-adjusted serum methadone concentration, close clinical monitoring should be considered, especially among patients with advanced cirrhosis. Still, serum methadone measurements can be considered a supplement to clinical assessments, taking into account intra-individual variations.
Details
- Language :
- English
- ISSN :
- 1545-0848
- Volume :
- 41
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of addictive diseases
- Publication Type :
- Academic Journal
- Accession number :
- 35356868
- Full Text :
- https://doi.org/10.1080/10550887.2022.2057140